Review
Immunology
Yuxian Wu, Mengpei Zhao, Na Gong, Feng Zhang, Wansheng Chen, Yaoyang Liu
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by clinical heterogeneity and unpredictable progression. The identification of sensitive and specific biomarkers for diagnosis and monitoring has been challenging due to the heterogeneous nature of lupus. Recent research has made significant progress in understanding how immune cells and cellular metabolism contribute to SLE pathogenesis. Dysregulation of the immune system and changes in metabolite profiles have been associated with SLE. Metabolite profiling may offer potential for novel biomarker discovery and mechanism exploration in SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Samson Pandam Salifu, Albert Doughan
Summary: Hematologic malignancies (HMs) have a high mortality rate, with one in two reported cases resulting in death. This study identified potential biomarkers and drug targets for HM management and treatment by analyzing RNA-seq data.
Review
Immunology
Zhe Geng, Cong Ye, Xiaojian Zhu
Summary: Patients with systemic rheumatic diseases have an increased risk of developing malignancies, which negatively affects their quality of life. The risk and types of malignancies can vary depending on the specific rheumatic disease. Possible mechanisms linking them include chronic inflammation and damage caused by rheumatic diseases, inability to clear oncogenic infections, shared etiology, and certain anti-rheumatic therapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Marta Lukaszewicz-Zajac, Sara Paczek, Barbara Mroczko
Summary: ADAM proteins play a crucial role in the pathogenesis of gastrointestinal cancers, potentially affecting patient prognosis. Their significance as potential prognostic biomarkers and therapeutic targets for GI malignancies is promising, but further research is needed for better understanding and treatment strategies.
Review
Oncology
Kai Sun, Huibao Yao, Peizhi Zhang, Yanning Sun, Jian Ma, Qinghua Xia
Summary: In recent years, there has been increasing attention on expanding the abundance of Circular RNAs (circRNAs), but the circRNAs that have significant functions in different diseases remain understudied. CircFNDC3B, a circRNA generated from the FNDC3B gene, has been extensively researched and shown to have multiple functions in different types of cancer and non-neoplastic diseases, making it a potential biomarker. Notably, circFNDC3B can exert its roles in diseases by binding to different microRNAs (miRNAs), interacting with RNA-binding proteins (RBPs), or encoding functional peptides. This paper provides a systematic summary of circRNA biogenesis and function, reviews the roles and molecular mechanisms of circFNDC3B and its target genes in various diseases, aiming to enhance our understanding of circRNA function and facilitate further research on circFNDC3B.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ann Moeller, Razelle Kurzrock, Gregory P. Botta, Jacob J. Adashek, Hitendra Patel, Suzanna Lee, Sarabjot Pabla, Mary K. Nesline, Jeffrey Conroy, Jason K. Sicklick, Shumei Kato
Summary: CSF1R expression plays a role in modulating tumor-associated macrophages and is considered a potential therapeutic target for immune modulation. However, the study found no difference in survival outcomes between high and low CSF1R expressors in a pan-cancer setting. Additionally, there was no significant difference in progression-free or overall survival in patients who received CSF1R inhibitors. Further research is needed to explore the impact of co-targeting specific immune checkpoint pathways in patients with high tumor CSF1R expression.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Review
Cell Biology
Soudeh Ghafouri-Fard, Arian Askari, Bashdar Mahmud Hussen, Mohammad Taheri, Majid Mokhtari
Summary: This review provides an overview of the crucial role TMPO-AS1 plays in carcinogenesis and assesses its potential as a marker for certain types of cancers.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Oncology
Nahid Alimoradi, Negar Firouzabadi, Reihaneh Fatehi
Summary: Metformin, as a first-line treatment for lowering blood glucose in type II diabetes, has been found to have therapeutic applications in cancer as well. By regulating miR expression, metformin may impact cancer treatment by influencing gene regulation and protein levels. The drug could potentially modify the expression of oncogenes and tumor suppressor genes, affecting cancer development.
CANCER CELL INTERNATIONAL
(2021)
Article
Environmental Sciences
S. Blanco, P. Moran, A. P. Diz, C. Olabarria, E. Vazquez
Summary: Increased heavy rainfall can reduce salinity in estuaries, affecting commercially important clam species and cockles. However, studies on the molecular response to hyposaline stress in bivalves are limited. This study found that the mantle-edge proteome was more responsive to sampling time than to hyposalinity, and reproductive stages influenced the stress response. The proteome profiles of some bivalve species were modulated by hyposalinity, involving proteins related to various biological pathways. However, essential proteins for an optimal osmotic stress response were found in small abundance. The response to osmotic stress in bivalves is complex and influenced by both controlled and uncontrolled variables.
ENVIRONMENTAL RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Ahmad Perwez, Khushnuma Wahabi, Moshahid A. Rizvi
Summary: Parkin, an E3 ubiquitin ligase, is deregulated in various human cancers and plays a crucial role in cancer pathogenesis by controlling major cancer hallmarks. Dysfunction of Parkin leads to genomic instability, perturbed cell cycle, and tumor progression. Existing studies highlight the tumor suppressive potential of Parkin, emphasizing its therapeutic implications and value as a biomarker.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Health Care Sciences & Services
Shiran Shapira, Dina Kazanov, Fatin Mdah, Hadas Yaakobi, Yair Herishanu, Chava Perry, Irit Avivi, Gilad Itchaki, Adi Shacham-Abulafia, Pia Raanani, Mori Hay-Levy, Gal Aiger, Jacob Mashiah, Shahar Lev-Ari, Nadir Arber
Summary: The study evaluated the sensitivity and specificity of a CD24/CD11b blood test for detecting hematological malignancies, revealing promising potential as a screening tool for these types of cancers.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Silvia Cavalli, Paola Adele Lonati, Maria Gerosa, Roberto Caporali, Rolando Cimaz, Cecilia Beatrice Chighizola
Summary: The complement system has a significant role in various rheumatologic conditions, including rheumatoid arthritis, psoriatic arthritis, Sjogren syndrome, systemic sclerosis, vasculitides, and dermatomyositis. Complement deposition is associated with disease severity, and serum complement levels may serve as potential markers for evaluating disease activity. In pregnancy, the complement system also plays a crucial role, and alterations in complement levels may be associated with pregnancy complications.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, Research & Experimental
Sureshbabu Ram Kumar Pandian, Kevin Kumar Vijayakumar, Selvaraj Kunjiappan, Ewa Babkiewicz, Piotr Maszczyk
Summary: Hematological malignancies are a heterogeneous group of blood tumors that often develop resistance to chemotherapy and result in relapse. Monoclonal antibody therapies have become the preferred treatment option. However, to improve patient outcomes, research is being conducted on effective drug delivery methods and new biomarkers.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Soudeh Ghafouri-Fard, Bashdar Mahmud Hussen, Elham Badrlou, Atefe Abak, Mohammad Taheri
Summary: miRNAs play a significant role in CRC by influencing the expression and activity of CRC-related pathways and interacting with long non-coding RNAs. Levels of miRNAs can be used to distinguish CRC patients from healthy controls. Despite evaluation of therapeutic application of miRNAs in CRC in animal models, it has not been verified in clinical settings.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Oncology
Zhichao Tian, Xiaohui Niu, Weitao Yao
Summary: Apatinib, a multitarget tyrosine kinase inhibitor marketed in China, has shown effectiveness in treating various malignancies such as GC, HCC, lung cancer, breast cancer, and more. This review provides valuable insights for the application and design of clinical trials involving apatinib.
FRONTIERS IN ONCOLOGY
(2021)